Top Markets
#1 Islamic Coin Islamic Coin +151.46%
#2 DOVU DOVU +50.32%
#3 Velvet Velvet +36.95%
#4 Black Phoenix Black Phoenix +34.87%
#5 Akedo Akedo +23.18%
#6 Fake World Assets Fake World Assets +21.86%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.21%
#8 DoubleZero DoubleZero +16.03%
#9 HOME HOME +11.90%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.90%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Rangering i aksjer #39944
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Aksjekurs
$0.00366968
Sist synkronisert: 2024-07-23
Markedsverdi
$291.42K
Endring (1 dag)
-0.81%
Endring (1 år)
0.00%
Land
US
Handel Bioasis Technologies Inc. (BTI)

Kategori

Healthcare
Historikk for aksjesplitt for Bioasis Technologies Inc. (BTI)
Aksjen Bioasis Technologies Inc. (symbol: BTI) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 14, 2026.
Én BTI-aksje kjøpt før Aug 14, 2026 tilsvarer i dag 0 BTI-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE